Nicolas Widmer

List of Publications by Year
in descending order

68 papers	3,132 citations	159585 30 h-index	155660 55 g-index
79 all docs	79 docs citations	79 times ranked	4073 citing authors

#	Article	IF	Citations
1	Full-scale simulations to improve disaster preparedness in hospital pharmacies. BMC Health Services Research, 2022, 22, .	2.2	4
2	Swiss Armed Forces deployment during the COVID-19 pandemic: militia pharmacy officersâ€™ roles and duties. BMJ Military Health, 2021, 167, 141-141.	0.9	1
3	Emergency and Disaster Preparedness of European Hospital Pharmacists: A Survey. Disaster Medicine and Public Health Preparedness, 2021, 15, 25-33.	1.3	11
4	Using risk analysis to anticipate and mitigate failures during a hospital pharmacy relocation. European Journal of Hospital Pharmacy, 2021, 28, ejhpharm-2020-002525.	1.1	2
5	Using risk analysis to ensure patientsâ€™ medication safety during hospital relocations and evacuations. European Journal of Hospital Pharmacy, 2021, 28, e171-e179.	1.1	0
6	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. JMIR Research Protocols, 2021, 10, e30090.	1.0	7
7	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	2
8	Elevated acute phase proteins affect pharmacokinetics in COVIDâ€19 trials: Lessons from the CounterCOVID â€•imatinib study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1497-1511.	2.5	8
9	Pharmaceutical Interventions on Hospital Discharge Prescriptions: Prospective Observational Study Highlighting Challenges for Community Pharmacists. Drugs - Real World Outcomes, 2021, , 1.	1.6	2
10	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring, 2020, 42, 33-44.	2.0	25
11	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. Frontiers in Pharmacology, 2020, 11, 177.	3.5	59
12	Population Pharmacokinetics of Erlotinib in Patients With Nonâ€“small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics, 2020, 42, 1302-1316.	2.5	13
13	Validation and clinical application of a multiplex high performance liquid chromatography â€“ tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1157, 122160.	2.3	38
14	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 124-136.	2.3	31
15	Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical Pharmacokinetics, 2018, 57, 1-6.	3.5	29
16	Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 341-347.	2.8	22
17	Transition of care: A set of pharmaceutical interventions improves hospital discharge prescriptions from an internal medicine ward. European Journal of Internal Medicine, 2017, 38, 30-37.	2.2	18
18	Prescription of Sedative Drugs During Hospital Stay: A Swiss Prospective Study. Drugs - Real World Outcomes, 2017, 4, 225-234.	1.6	13

#	Article	IF	Citations
19	Biases affecting injected doses of an experimental drug during clinical trials. Trials, 2016, 17, 321.	1.6	0
20	The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine. TrAC - Trends in Analytical Chemistry, 2016, 84, 5-13.	11.4	29
21	Erlotinib. Therapeutic Drug Monitoring, 2015, 37, 2-21.	2.0	36
22	Therapeutic drug monitoring of targeted anticancer therapy. Biomarkers in Medicine, 2015, 9, 887-893.	1.4	24
23	Representation of Medical Guidelines with a Computer Interpretable Model. International Journal on Artificial Intelligence Tools, 2014, 23, 1460003.	1.0	6
24	Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemotherapy and Pharmacology, 2014, 74, 1307-1319.	2.3	60
25	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. British Journal of Clinical Pharmacology, 2014, 78, 1090-1101.	2.4	50
26	Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine, 2014, 6, 372-383.	6.9	311
27	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2014, 69, 2489-2498.	3.0	31
28	Large-scale imatinib doseâ€“concentrationâ€“effect study in CML patients under routine care conditions. Leukemia Research, 2014, 38, 764-772.	0.8	37
29	Review of therapeutic drug monitoring of anticancer drugs part two â€“ Targeted therapies. European Journal of Cancer, 2014, 50, 2020-2036.	2.8	248
30	Therapeutic drug monitoring in cancer â€“ Are we missing a trick?. European Journal of Cancer, 2014, 50, 2005-2009.	2.8	79
31	Review of therapeutic drug monitoring of anticancer drugs part 1 â€“ Cytotoxics. European Journal of Cancer, 2014, 50, 2010-2019.	2.8	205
32	OC014â€”Clinical Usefulness Of Therapeutic Concentration Monitoring For Imatinib Dosage Individualization: Results From The Randomized Controlled I-Come Trial. Clinical Therapeutics, 2013, 35, e6.	2.5	2
33	Personalized Drug Administrations Using Support Vector Machine. BioNanoScience, 2013, 3, 378-393.	3.5	2
34	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2013, 75, 1007-1018.	2.4	33
35	Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools. Clinical Pharmacokinetics, 2013, 52, 9-22.	3.5	141
36	OC005â€”Biases On The Administered Parenteral Doses Of An Experimental Drug During Phase I Clinical Trials. Clinical Therapeutics, 2013, 35, e2-e3.	2.5	0

#	Article	IF	Citations
37	Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes. Therapeutic Drug Monitoring, 2013, 35, 150-167.	2.0	36
38	Long-term Prospective Population PK Study in GIST Patientsâ€"Letter. Clinical Cancer Research, 2013, 19, 949-949.	7.0	9
39	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 28-35.	2.1	86
40	Response to Calcagno Comment on â€œHigher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluidâ€• Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, e14-e15.	2.1	1
41	A Drug Administration Decision Support System. , 2012, , .		6
42	Therapeutic Drug Monitoring of Imatinib. Clinical Pharmacokinetics, 2012, 51, 187-201.	3.5	43
43	An agenda for UK clinical pharmacology: Monitoring drug therapy. British Journal of Clinical Pharmacology, 2012, 73, 917-923.	2.4	27
44	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2
45	Example-based support vector machine for drug concentration analysis. , 2011, 2011, 153-7.		14
46	Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?. Cancer Treatment Reviews, 2011, 37, 291-299.	7.7	61
47	Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncology, The, 2011, 12, 9-11.	10.7	22
48	12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2011, 33, 469-559.	2.0	7
49	Personalized modeling for drug concentration prediction using Support Vector Machine. , 2011, , .		4
50	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood, 2011, 117, e75-e87.	1.4	202
51	Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia. Leukemia Research, 2010, 34, 698-699.	0.8	5
52	Imatinib plasma levels: correlation with clinical benefit in GIST patients. British Journal of Cancer, 2010, 102, 1198-1199.	6.4	35
53	siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. Drug Metabolism Letters, 2010, 4, 114-119.	0.8	24
54	Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. Clinical Pharmacokinetics, 2010, 49, 741-765.	3.5	48

#	Article	IF	Citations
55	Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- N -Oxide, Anidulafungin, and Caspofungin. Antimicrobial Agents and Chemotherapy, 2010, 54, 5303-5315.	3.2	108
56	Cardiovascular drug interactions with tyrosine kinase inhibitors. Cardiovascular Medicine(Switzerland), 2010, 13, .	0.0	1
57	Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1982-1996.	2.3	172
58	Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatographyâ€“mass spectrometry. Journal of Mass Spectrometry, 2008, 43, 736-752.	1.6	52
59	Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. British Journal of Cancer, 2008, 98, 1633-1640.	6.4	106
60	Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia, 2007, 21, 1561-1562.	7.2	44
61	Reply to Zong et al.. Leukemia, 2007, 21, 1563-1564.	7.2	2
62	Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. Journal of Hepatology, 2006, 44, 167-175.	3.7	80
63	Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. British Journal of Clinical Pharmacology, 2006, 62, 97-112.	2.4	161
64	Formulation Optimization in a University Hospital: The Example of Pediatric Solutions of the ACE Inhibitor Captopril. Chimia, 2005, 59, 357-358.	0.6	0
65	Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia. Dermatology, 2005, 211, 363-365.	2.1	44
66	Determination of imatinib (GleevecÂ®) in human plasma by solid-phase extractionâ€“liquid chromatographyâ€“ultraviolet absorbance detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 803, 285-292.	2.3	52
67	Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood, 2003, 102, 1142-1142.	1.4	66
68	Setting-up a multi-center human research: Systematic observation during a Swiss clinical trial. Bioethica Forum, 0, , .	0.0	0